PDCD1 and cancer: This pilot trial indicates that CRISPR/Cas9 is feasible in combination with cancer immunotherapy and could increase persistence of adoptively transferred cells in patients, by limiting exhaustion through knockdown of PD-1 in the T cell graft [111].